Literature DB >> 24405893

miR-138 inhibits proliferation by targeting 3-phosphoinositide-dependent protein kinase-1 in non-small cell lung cancer cells.

Xian-wei Ye1, Hong Yu, Yan-kun Jin, Xiao-ting Jing, Mei Xu, Zi-fen Wan, Xiang-yan Zhang.   

Abstract

OBJECTIVE: Underlying mechanisms of non-small cell lung cancer (NSCLC) development remain poorly understood. miR-138 and 3-phosphoinositide-dependent protein kinase-1 (PDK1) have been reported to be involved in the genesis of NSCLC. The aim of this study was to investigate the role and mechanisms of miR-138 and PDK1 in human NSCLC cells.
METHODS: The effect of miR-138 on proliferation of A549 lung cancer cells was first examined using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide assay. The expression of PDK1 in A549 lung cancer cells was assessed by real-time polymerase chain reaction further. A luciferase reporter activity assay was conducted to confirm target association between miR-138 and 3' untranslated region (3'-UTR) of PDK1. Finally, the role of PDK1 on proliferation of A549 cells was evaluated by transefection of PDK1 small interfering RNA (siRNA).
RESULTS: Proliferation of A549 lung cancer cells was suppressed by miR-138 in a concentration-dependent manner. Furthermore, miR-138 can bind to the 3'-UTR of PDK1 and downregulate expression of PDK1 at both mRNA and protein levels. Knockdown of PDK1 by siRNA significantly inhibits the proliferation of A549 lung cancer cells.
CONCLUSIONS: These findings suggest that miR-138 as a potential tumor suppressor could inhibit cell proliferation by targeting PDK1 in NSCLC cells, which could be employed as a potential therapeutic target for miRNA-based NSCLC therapy.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  3-phosphoinositide-dependent protein kinase-1; cell proliferation; miR-138; non-small cell lung cancer; siRNA

Mesh:

Substances:

Year:  2014        PMID: 24405893     DOI: 10.1111/crj.12100

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  27 in total

1.  Prognostic potential of microRNA-138 and its target mRNA PDK1 in sera for patients with non-small cell lung cancer.

Authors:  Lihong Han; Guoxiu Zhang; Nali Zhang; Haiyan Li; Yanyan Liu; Aiguo Fu; Youguang Zheng
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

2.  MicroRNA-138 targets SP1 to inhibit the proliferation, migration and invasion of hepatocellular carcinoma cells.

Authors:  Chongzhong Liu; Jiankang Zhu; Fengyue Liu; Yadong Wang; Min Zhu
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

3.  MicroRNA-138 inhibits proliferation, migration and invasion through targeting hTERT in cervical cancer.

Authors:  Na Zhou; Dan Fei; Shan Zong; Mingyue Zhang; Ying Yue
Journal:  Oncol Lett       Date:  2016-08-23       Impact factor: 2.967

4.  miR-297 acts as an oncogene by targeting GPC5 in lung adenocarcinoma.

Authors:  Yunchuan Sun; Jianyong Zhao; Xiaoming Yin; Xiangkun Yuan; Jianfei Guo; Jianqiang Bi
Journal:  Cell Prolif       Date:  2016-08-24       Impact factor: 6.831

5.  Salidroside alleviates high-glucose-induced injury in retinal pigment epithelial cell line ARPE-19 by down-regulation of miR-138.

Authors:  Cheng Qian; Shenzhi Liang; Guangming Wan; Yi Dong; Taiying Lu; Panshi Yan
Journal:  RNA Biol       Date:  2019-07-11       Impact factor: 4.652

6.  MicroRNA-138 negatively regulates non-small cell lung cancer cells through the interaction with cyclin D3.

Authors:  Li-Ping Han; Tian Fu; Yong Lin; Jian-Long Miao; Qiu-Fang Jiang
Journal:  Tumour Biol       Date:  2015-07-23

7.  miRs-138 and -424 control palmitoylation-dependent CD95-mediated cell death by targeting acyl protein thioesterases 1 and 2 in CLL.

Authors:  Valeska Berg; Marion Rusch; Nachiket Vartak; Christian Jüngst; Astrid Schauss; Herbert Waldmann; Christian Hedberg; Christian P Pallasch; Philippe I H Bastiaens; Michael Hallek; Clemens-Martin Wendtner; Lukas P Frenzel
Journal:  Blood       Date:  2015-02-10       Impact factor: 22.113

8.  miR-320 inhibited ovarian cancer oncogenicity via targeting TWIST1 expression.

Authors:  Chunyang Li; Ping Duan; Jianguang Wang; Xiaosheng Lu; Jing Cheng
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

9.  Vimentin regulates neuroplasticity in transected spinal cord rats associated with micRNA138.

Authors:  Bao-Jiang Qian; Ling You; Fei-Fei Shang; Jia Liu; Ping Dai; Na Lin; Mu He; Ran Liu; Yuan Zhang; Yang Xu; Yun-Hui Zhang; Ting-Hua Wang
Journal:  Mol Neurobiol       Date:  2014-05-31       Impact factor: 5.590

10.  MicroRNA-138 suppresses cell proliferation and invasion of renal cell carcinoma by directly targeting SOX9.

Authors:  Bo Hu; Jianbo Wang; Xunbo Jin
Journal:  Oncol Lett       Date:  2017-10-10       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.